Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,026
archived clinical trials in
Epilepsy

Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Austin Epilepsy Care Center
mi
from
Austin, TX
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Austin Epilepsy Care Center
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
VCU Medical Center
mi
from
Richmond, VA
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Behavioral and Educational Tools to Improve Epilepsy Care
Behavioral and Educational Tools to Improve Epilepsy Care
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
mi
from
New York, NY
Behavioral and Educational Tools to Improve Epilepsy Care
Behavioral and Educational Tools to Improve Epilepsy Care
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Florida Gainesville
mi
from
Gainesville, FL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Florida Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Miami Children's Hospital
mi
from
Miami, FL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Medical College of Georgia at Georgia Regents University
mi
from
Augusta, GA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Medical College of Georgia at Georgia Regents University
mi
from
Augusta, GA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center / Epilepsy Center
mi
from
Chicago, IL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center / Epilepsy Center
mi
from
Chicago, IL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Via Christi Comprehensive Epilepsy Center
mi
from
Wichita, KA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Via Christi Comprehensive Epilepsy Center
mi
from
Wichita, KA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Louisiana State University Epilepsy Center of Excellence
mi
from
New Orleans, LA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Louisiana State University Epilepsy Center of Excellence
mi
from
New Orleans, LA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Saint Barnabas Medical Center
mi
from
Livingston, NJ
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Saint Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Columbia University / Columbia Presbyterian Medical Center
mi
from
New York, NY
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Columbia University / Columbia Presbyterian Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
George Washington University
mi
from
Washington,
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Paducah, KY
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bethesda, MD
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burlington, MA
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Grand Rapids, MI
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tupelo, MS
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chesterfield, MO
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chesterfield, MO
Click here to add this to my saved trials